Peptide and Oligonucleotide CDMO Market Growth, Size, Trends , Analysis 2034
Global Peptide and Oligonucleotide CDMO Market Growth, Size, Trends Analysis- By Product, By Service Type, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jun-2025 | Report ID: HLCA25184 | Pages: 1 - 244 | Formats*: |
| Category : Healthcare | |||
Peptide and Oligonucleotide CDMO Market Introduction and Overview
According to SPER Market Research, the Global Peptide and Oligonucleotide CDMO Market is estimated to reach USD 9212.42 million by 2034 with a CAGR of 12.46%.
The report includes an in-depth analysis of the Global Peptide and Oligonucleotide CDMO Market, including market size and trends, product mix, Applications, and supplier analysis. The increasing use of peptides and oligonucleotides in therapeutics, driven by the shift toward personalized medicine, is fueling demand for specialized CDMOs. This trend is further supported by regulatory efforts from agencies like the EMA and FDA to establish clear manufacturing guidelines, collectively contributing to the rapid and lucrative growth of the peptide and oligonucleotide CDMO market. Oligonucleotides and peptides are increasingly used to treat various conditions like cancer, metabolic, and genetic disorders. Advances in synthesis and manufacturing have expanded their therapeutic applications, driving demand for CDMOs with specialized expertise.
By Product:
The peptides segment holds the largest share of the market, driven by a growing pipeline of peptide-based products and increased investment from pharmaceutical and biopharmaceutical companies targeting various diseases. This trend is expected to continue, supported by capacity expansions like EUROAPI’s advanced manufacturing upgrade in Germany. Meanwhile, the oligonucleotides segment is projected to grow rapidly, fueled by rising clinical investments, a surge in pipeline therapeutics, and more CDMOs entering the market to meet the growing demand.
By Service Type:
The contract manufacturing segment dominates the peptide and oligonucleotide CDMO market, driven by the increasing number of CDMOs entering the space and the significant production costs associated with these therapeutics. To manage expenses, sponsor companies increasingly outsource large-scale manufacturing to specialized contract manufacturers. Meanwhile, the contract development segment is experiencing strong growth, driven by the rising need for specialized expertise and advanced technologies in developing peptide and oligonucleotide-based drugs, which many CDMOs are well-equipped to provide.
By End Use:
Biopharmaceutical companies lead the market, driven by rising investments in peptide and oligonucleotide drug development. Collaborations, such as the one between Vanda Pharmaceuticals and OliPass Corporation to develop antisense oligonucleotide molecules, highlight this trend. Meanwhile, pharmaceutical companies are also showing steady growth, supported by increased involvement in innovative drug development. Many are outsourcing manufacturing and development to CDMOs, which offer specialized expertise and efficient processes that help accelerate timelines and bring therapies to market more quickly.
Regional Insights:
North America holds the largest market share, driven by the presence of established CDMOs like PolyPeptide Group, STA Pharmaceutical, and Bachem, which specialize in peptide and oligonucleotide development. The U.S. leads the region, with many pharmaceutical companies outsourcing manufacturing to trusted local CROs known for high-quality services. Europe is expected to outpace North America due to strong players like EUROAPI and PolyPeptide Group, which have robust development pipelines. Meanwhile, Asia Pacific is emerging as the fastest-growing region, benefiting from favorable regulations, cost-effective clinical research in countries like China and India, and the presence of FDA- and EMA-approved facilities that are attracting increasing foreign investment.
Market Competitive Landscape:
The global Peptide and Oligonucleotide CDMO Market is highly consolidated. Some of the market key players are PolyPeptide Group, STA Pharmaceutical Co. Ltd., Merck KGaA, EUROAPI, Curia Global, Inc., CordenPharm, and Sylentis, S.A., Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd.,
Recent Developments:
In August 2023, EUROAPI completed the acquisition of BianoGMP, reinforcing its presence in the CDMO industry and expanding its expertise in the rapidly growing oligonucleotide market.
In May 2023, PolyPeptide and Numaferm entered into a partnership focused on the development and production of peptides.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Service Type, By End Use |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | PolyPeptide Group, STA Pharmaceutical Co. Ltd., Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd., Merck KGaA, EUROAPI, Curia Global, Inc., CordenPharm, and Sylentis, S.A. |
Key Topics Covered in the Report
- Global Peptide and Oligonucleotide CDMO Market Size (FY’2021-FY’2034)
- Overview of Global Peptide and Oligonucleotide CDMO Market
- Segmentation of Global Peptide and Oligonucleotide CDMO Market By Product (Peptides, Oligonucleotides)
- Segmentation of Global Peptide and Oligonucleotide CDMO Market By Service (Contract Development, Contract Manufacturing)
- Segmentation of Global Peptide and Oligonucleotide CDMO Market By End Use (Pharmaceutical Companies, Biopharmaceutical Companies, Others)
- Statistical Snap of Global Peptide and Oligonucleotide CDMO Market
- Expansion Analysis of Global Peptide and Oligonucleotide CDMO Market
- Problems and Obstacles in Global Peptide and Oligonucleotide CDMO Market
- Competitive Landscape in the Global Peptide and Oligonucleotide CDMO Market
- Details on Current Investment in Global Peptide and Oligonucleotide CDMO Market
- Competitive Analysis of Global Peptide and Oligonucleotide CDMO Market
- Prominent Players in the Global Peptide and Oligonucleotide CDMO Market
- SWOT Analysis of Global Peptide and Oligonucleotide CDMO Market
- Global Peptide and Oligonucleotide CDMO Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats5.2.PESTEL Analysis5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape5.3.PORTER’s Five Forces5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Peptide and Oligonucleotide CDMO Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Peptide and Oligonucleotide CDMO Market
7.Global Peptide and Oligonucleotide CDMO Market, By Product, (USD Million) 2021-2034
7.1.Peptides7.2.Oligonucleotides
8.Global Peptide and Oligonucleotide CDMO Market, By Service Type, (USD Million) 2021-2034
8.1.Contract Development8.2.Contract Manufacturing
9.Global Peptide and Oligonucleotide CDMO Market, By End Use, (USD Million) 2021-2034
9.1.Pharmaceutical Companies9.2.Biopharmaceutical Companies9.3.Others
10.Global Peptide and Oligonucleotide CDMO Market, (USD Million) 2021-2034
10.1.Global Peptide and Oligonucleotide CDMO Market Size and Market Share
11.Global Peptide and Oligonucleotide CDMO Market, By Region, 2021-2034 (USD Million)
11.1.Asia-Pacific11.1.1.Australia11.1.2.China11.1.3.India11.1.4.Japan11.1.5.South Korea11.1.6.Rest of Asia-Pacific11.2.Europe11.2.1.France11.2.2.Germany11.2.3.Italy11.2.4.Spain11.2.5.United Kingdom11.2.6.Rest of Europe11.3.Middle East and Africa11.3.1.Kingdom of Saudi Arabia11.3.2.United Arab Emirates11.3.3.Qatar11.3.4.South Africa11.3.5.Egypt11.3.6.Morocco11.3.7.Nigeria11.3.8.Rest of Middle-East and Africa11.4.North America11.4.1.Canada11.4.2.Mexico11.4.3.United States11.5.Latin America11.5.1.Argentina11.5.2.Brazil11.5.3.Rest of Latin America
12.Company Profile
12.1.PolyPeptide Group12.1.1.Company details12.1.2.Financial outlook12.1.3.Product summary12.1.4.Recent developments12.2.STA Pharmaceutical Co. Ltd.12.2.1.Company details12.2.2.Financial outlook12.2.3.Product summary12.2.4.Recent developments12.3.Bachem12.3.1.Company details12.3.2.Financial outlook12.3.3.Product summary12.3.4.Recent developments12.4.Creative Peptides12.4.1.Company details12.4.2.Financial outlook12.4.3.Product summary12.4.4.Recent developments12.5.Aurigene Pharmaceutical Services Ltd.12.5.1.Company details12.5.2.Financial outlook12.5.3.Product summary12.5.4.Recent developments12.6.Merck KGaA12.6.1.Company details12.6.2.Financial outlook12.6.3.Product summary12.6.4.Recent developments12.7.EUROAPI12.7.1.Company details12.7.2.Financial outlook12.7.3.Product summary12.7.4.Recent developments12.8.Curia Global, Inc.12.8.1.Company details12.8.2.Financial outlook12.8.3.Product summary12.8.4.Recent developments12.9.CordenPharm12.9.1.Company details12.9.2.Financial outlook12.9.3.Product summary12.9.4.Recent developments12.10.Sylentis, S.A.12.10.1.Company details12.10.2.Financial outlook12.10.3.Product summary12.10.4.Recent developments12.11.Others
13.Conclusion
14.List of Abbreviations
15.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
"
The report includes an in-depth analysis of the Global Peptide and Oligonucleotide CDMO Market, including market size and trends, product mix, Applications, and supplier analysis."
the Peptide and Oligonucleotide CDMO Market is projected to reach USD 9212.42 by 2034, growing at a CAGR of 12.46% during the forecast period.
the Peptide and Oligonucleotide CDMO Market size from 2025. The Market is expected to reach USD 9212.42 by 2034, at a CAGR of 25.78% during the forecast period.
the Peptide and Oligonucleotide CDMO Market CAGR of 12.46% during the forecast period.
You can get the sample pages by clicking the link - Click Here
the Peptide and Oligonucleotide CDMO Market size is USD 9212.42 from 2025 to 2034.
"the Peptide and Oligonucleotide CDMO Market covered By Product, By Service Type, By End Use"
The North America is anticipated to have the highest Market share in the Peptide and Oligonucleotide CDMO Market .
PolyPeptide Group, STA Pharmaceutical Co. Ltd., Bachem, Creative Peptides, Aurigene Pharmaceutical Services Ltd., Merck KGaA, EUROAPI, Curia Global, Inc., CordenPharm, and Sylentis, S.A.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
